FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020050105> ?p ?o ?g. }

• W2020050105 endingPage "255" @default.
• W2020050105 startingPage "248" @default.
• W2020050105 abstract "Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon.A Phase I study was completed of subcutaneous (s.c.) HHT in patients with CML in accelerated or blast phases and demonstrated efficacy and good tolerance at the same doses used by intravenous (i.v.) administration. The maximal tolerated dose (MTD) was 1.25 mg/m(2) s.c. twice daily. The cohort was then expanded to treated at the MTD to include patients in late chronic phase CML after imatinib failure. Therapy consisted of an i.v. loading dose of HHT 2.5 mg/m(2) over 24 hours, followed by 1.25 mg/m(2) s.c. twice daily for 14 days every 28 days until remission, then for 7 days every 28 days. Six patients (median age, 53 years) who had failed imatinib were treated and 5 were evaluable. Patients received a median of 4.5 courses of s.c. HHT.Complete hematologic remission was obtained in all 5 evaluable patients and 3 had cytogenetic (CG) responses: 1 complete and 2 minor. The 2 patients with BCR-ABL kinase domain mutations at the start of therapy with HHT had a CG response and in both instances the mutations became undetectable. All patients developed myelosuppression and 3 had their HHT dose reduced due to prolonged neutropenia. Nonhematologic toxicity was mild and manageable.Subcutaneous HHT is well tolerated and may have clinical activity in patients with CML after imatinib failure." @default.
• W2020050105 created "2016-06-24" @default.
• W2020050105 creator A5002557166 @default.
• W2020050105 creator A5006104041 @default.
• W2020050105 creator A5015140142 @default.
• W2020050105 creator A5019337932 @default.
• W2020050105 creator A5021892503 @default.
• W2020050105 creator A5046097970 @default.
• W2020050105 creator A5061026876 @default.
• W2020050105 creator A5061285204 @default.
• W2020050105 creator A5084290698 @default.
• W2020050105 creator A5085521139 @default.
• W2020050105 creator A5090435894 @default.
• W2020050105 date "2007-01-01" @default.
• W2020050105 modified "2023-10-15" @default.
• W2020050105 title "Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy" @default.
• W2020050105 cites W1912502835 @default.
• W2020050105 cites W1974565168 @default.
• W2020050105 cites W1991743074 @default.
• W2020050105 cites W1996332917 @default.
• W2020050105 cites W2011474502 @default.
• W2020050105 cites W2016069264 @default.
• W2020050105 cites W2028959752 @default.
• W2020050105 cites W2048740168 @default.
• W2020050105 cites W2059568372 @default.
• W2020050105 cites W2074740152 @default.
• W2020050105 cites W2084887234 @default.
• W2020050105 cites W2085959661 @default.
• W2020050105 cites W2087126873 @default.
• W2020050105 cites W2088964348 @default.
• W2020050105 cites W2097255369 @default.
• W2020050105 cites W2097946794 @default.
• W2020050105 cites W2101390452 @default.
• W2020050105 cites W2107218745 @default.
• W2020050105 cites W2113703021 @default.
• W2020050105 cites W2117569938 @default.
• W2020050105 cites W2120033838 @default.
• W2020050105 cites W2142969636 @default.
• W2020050105 cites W2169452890 @default.
• W2020050105 cites W2171722798 @default.
• W2020050105 cites W2326622487 @default.
• W2020050105 cites W2342728849 @default.
• W2020050105 cites W4238920715 @default.
• W2020050105 doi "https://doi.org/10.1002/cncr.22398" @default.
• W2020050105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17154172" @default.
• W2020050105 hasPublicationYear "2007" @default.
• W2020050105 type Work @default.
• W2020050105 sameAs 2020050105 @default.
• W2020050105 citedByCount "119" @default.
• W2020050105 countsByYear W20200501052012 @default.
• W2020050105 countsByYear W20200501052013 @default.
• W2020050105 countsByYear W20200501052014 @default.
• W2020050105 countsByYear W20200501052015 @default.
• W2020050105 countsByYear W20200501052016 @default.
• W2020050105 countsByYear W20200501052017 @default.
• W2020050105 countsByYear W20200501052018 @default.
• W2020050105 countsByYear W20200501052019 @default.
• W2020050105 countsByYear W20200501052020 @default.
• W2020050105 countsByYear W20200501052021 @default.
• W2020050105 countsByYear W20200501052022 @default.
• W2020050105 crossrefType "journal-article" @default.
• W2020050105 hasAuthorship W2020050105A5002557166 @default.
• W2020050105 hasAuthorship W2020050105A5006104041 @default.
• W2020050105 hasAuthorship W2020050105A5015140142 @default.
• W2020050105 hasAuthorship W2020050105A5019337932 @default.
• W2020050105 hasAuthorship W2020050105A5021892503 @default.
• W2020050105 hasAuthorship W2020050105A5046097970 @default.
• W2020050105 hasAuthorship W2020050105A5061026876 @default.
• W2020050105 hasAuthorship W2020050105A5061285204 @default.
• W2020050105 hasAuthorship W2020050105A5084290698 @default.
• W2020050105 hasAuthorship W2020050105A5085521139 @default.
• W2020050105 hasAuthorship W2020050105A5090435894 @default.
• W2020050105 hasBestOaLocation W20200501051 @default.
• W2020050105 hasConcept C126322002 @default.
• W2020050105 hasConcept C141071460 @default.
• W2020050105 hasConcept C2776390293 @default.
• W2020050105 hasConcept C2776960273 @default.
• W2020050105 hasConcept C2777063308 @default.
• W2020050105 hasConcept C2777583451 @default.
• W2020050105 hasConcept C2778461978 @default.
• W2020050105 hasConcept C2778729363 @default.
• W2020050105 hasConcept C2779282312 @default.
• W2020050105 hasConcept C2910157418 @default.
• W2020050105 hasConcept C29730261 @default.
• W2020050105 hasConcept C71924100 @default.
• W2020050105 hasConcept C90924648 @default.
• W2020050105 hasConceptScore W2020050105C126322002 @default.
• W2020050105 hasConceptScore W2020050105C141071460 @default.
• W2020050105 hasConceptScore W2020050105C2776390293 @default.
• W2020050105 hasConceptScore W2020050105C2776960273 @default.
• W2020050105 hasConceptScore W2020050105C2777063308 @default.
• W2020050105 hasConceptScore W2020050105C2777583451 @default.
• W2020050105 hasConceptScore W2020050105C2778461978 @default.
• W2020050105 hasConceptScore W2020050105C2778729363 @default.
• W2020050105 hasConceptScore W2020050105C2779282312 @default.
• W2020050105 hasConceptScore W2020050105C2910157418 @default.
• W2020050105 hasConceptScore W2020050105C29730261 @default.
• W2020050105 hasConceptScore W2020050105C71924100 @default.

• next